Transcription of TAGRISSO PRESCRIBING INFORMATION
{{id}} {{{paragraph}}}
Example: biology
TAGRISSO PRESCRIBING INFORMATION
US-23584 HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the INFORMATION needed to use TAGRISSO safely and effectively. See full PRESCRIBING INFORMATION for (osimertinib) tablets, for oral useInitial Approval: 2015--------------------------------- RECENT MAJOR CHANGES --------------------------------Indicati ons and Usage ( ) 4/2018 Dosage and Administration ( ) 4/2018 Warnings and Precautions ( , ) 4/2018--------------------------------- INDICATIONS AND USAGE ---------------------------------TAGRISS O is a kinase inhibitor indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2020. FULL PRESCRIBING INFORMATION: CONTENTS * 1 INDICATIONS AND USAGE. 1.1 Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) 1.2 First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: